|
|
|||
|
|
Name : Heba Mohammed Hussein
Date of Birth : 22/3/1978
Nationality : Egyptian
Previous Degree : Bs.C.
Registration Date : 10/4/2003
Awarding Date : 11/2/2008
Supervisors : Prof. Dr. Mohamed Marzouk Mohamed
Prof. Dr. Hany Alfons Abdou
Examiners : Prof. Dr. Mohamed Marzouk Mohamed
Prof. Dr. Jeffrey R. Fry
Prof. Dr. Mohamed Nagy Mohamed Mosaad Hussein
Title of Thesis :
“Biochemical studies on the interaction between non-steroidal anti-inflammatory and anti-tuberculosis drugs in rats”
Key Words : Mepacure® (DDB+ silymarin) – Rhuma-cure® (rofecoxib) - Rimactazid® and Rhuma-cure®.
Summary :
The present study was carried out to evaluate the possible hepatoprotective effect of Mepacure® (DDB+ silymarin) in protecting against liver injury induced by Rhuma-cure® (rofecoxib), Rimactazid® (rifampicin+isoniazid) or their combination in male albino rats. Rats were divided into eight groups, received a daily dose as the following: group one received vehicle (water and 2% tween 80), group two received Rimactazid® (rifampicin 162 mg/kg.bwt and isoniazid 81 mg/kg b.wt), group three received Rhuma-cure® (rofecoxib 6.75 mg/kg b.wt), group four received Mepacure® (13.5 mg/kg b.wt silymarin and 8.1 mg/kg b.wt DDB), group five received Rimactazid® and Rhuma-cure®, group six received Rimactazid® and Mepacure®, group seven received Rhuma-cure® and Mepacure® and group eight received Rimactazid® and Rhuma-cure® and Mepacure®. Blood samples were withdrawn after 24 hours, 3 and 6 weeks of treatment. The following parameters were determined in blood serum: total protein, albumin, globulin, A/G ratio, glucose, triglycerides, cholesterol, bilirubin, ALT, AST and ALP. Significant alterations were revealed in some of the studied parameters due to the treatment with both antituberculosis and anti-inflammatory drug. Meanwhile, Mepacure® drug reversed some of these abnormal alterations as compared to their base line.
Rights of Design © is reserved to Faculty of Science
Designed and Directed by A.H.A